Charles Theuer - 02 Nov 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 02 Nov 2022
Net transactions value: +$9,540
Form type: 4
Filing time: 03 Nov 2022, 06:00:13 UTC
Previous filing: 11 Oct 2022
Next filing: 04 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock	Purchase	$9,540	+6,000	+2.1%	$1.59	287,018	02 Nov 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5897 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2	Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2022.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5897 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Includes 3,500 shares acquired by the Reporting Person under the Issuer's 2015 Employee Stock Purchase Plan on October 20, 2022.